Gilead’s newly bought immunotherapy drug scores at ASCO

The company presented Phase Ib data for magrolimab, a CD47 inhibitor, in AML and MDS. An interviewed executive and an investigator expressed particular excitement about complete responses in a poor-prognosis patient subset, in addition to the general AML population.